Trailblazer-ALZ Trial… Now Enrolling

Palm Beach Neurological Center is participating in a clinical trial to examine if an investigational drug may help slow or stop memory loss in people with early stages of Alzheimer’s disease. It is an “Investigational” drug, meaning it has not yet been approved by regulatory authorities for doctors to prescribe in their everyday practice.

Benefits of the Trailblazer-ALZ Study:

As we age,

Delphia Study for Dementia with Lewy Bodies (DLB)…Enrolling


Palm Beach Neurological Center is participating in a clinical research study to evaluate an investigational drug called “Delphia” for patients suffering from Dementia with Lewy Bodies. An investigational drug is not yet approved for use by the public. Doctors perform these studies to make sure it is safe and to see if it is helpful for patients with Dementia with Lewy Bodies.

Alzheimer’s Prevention Initiative (API) Generation Study 2…Enrolling


Palm Beach Neurological Center is participating in a global clinical research study to prevent or delay Alzheimer’s disease in cognitively healthy, older individuals that have been identified with one or two major genetic risk factors for the onset of Alzheimer’s disease.

The Generation Study 2 is a randomized, double-blind, placebo-controlled trial that tests  whether the BACE inhibitor CNP520 can prevent or delay the symptoms of Alzheimer’s in people at a particularly higher risk due to their age. 

Potential Treatment for Early Onset Alzheimer’s…Ongoing


A global clinical research study assessing the effectiveness and safety of an investigational medication designed to slow the progression of early Alzheimer’s disease.

The ENGAGE study is split into two phases: a placebo-controlled phase, and an optional long-term extension phase.

In the placebo-controlled phase, eligible participants will have a 2-in-3 chance of receiving the investigational medication and a 1-in-3 chance of receiving the placebo.

The MissionAD study for early stages of Alzheimer’s disease…Currently Enrolling


The MissionAD study program is a clinical research program testing an investigational drug for the early stages of Alzheimer’s disease. (“Investigational” means the drug isn’t yet approved for use by the public.) Doctors are studying this investigational drug to make sure it is safe and to see if it may help people with Alzheimer’s disease in the future.

Behavioral-variant frontotemporal dementia


Objective: To identify distinct behavioral phenotypes of behavioral-variant frontotemporal dementia (bvFTD) and to elucidate differences in functional, neuroimaging, and progression to residential care placement.

Methods: Eighty-eight patients with bvFTD were included in a cluster analysis applying levels of disinhibition and apathy (Cambridge Behavioural Inventory-Revised) to identify phenotypic subgroups. Between-group (Kruskal-Wallis,

Rethinking cognition in Parkinson disease – Phosphodiesterase 4

The nosology and treatment options for cognitive impairment in Parkinson disease (PD) remains perhaps the greatest unmet clinical need.1 The reported frequency of mild cognitive impairment (MCI) in newly diagnosed PD has ranged from 22% to 43%.2,3 A proportion of those with PD-MCI progress to PD dementia (PDD), the prevalence of which is variously estimated between 24% and 31%,

Slowing Gait and Risk for Cognitive Impairment

Originally posted on

Methods: We assessed a cohort of older adults (n = 175, mean age 73 years, 57% female, 65% white) with repeated measures of gait speed over 14 years, MRI for gray matter volume (GMV) at year 10 or 11, and adjudicated cognitive status at year 14. Gait slowing was calculated by bayesian slopes corrected for intercepts,

Dementia with Lewy bodies: Diagnosis is only skin deep?

Originally posted on

Dementia with Lewy bodies (DLB) is currently diagnosed clinically by identifying dementia in combination with a number of hallmark features: REM sleep behavior disorder (RBD), prominent visual hallucinations, parkinsonism, and marked fluctuations of cognition and alertness.1 DLB is often underdiagnosed, suggesting a role for biomarkers. The main differential diagnosis of DLB is Alzheimer disease (AD);